FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/fda-approves-leqembi-extending-alzheimers-treatment-to-more-patients-88339173July 6, 2023 4:50 pm ETBiogen developed the drug with Eisai, which said Leqembi could generate $7 billion in annual sales globally by 2030.is on its way to many more patients across the U.S.Continue reading your article with

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Source: CNBC - 🏆 12. / 72 Read more »

Op-ed: Medicare agency limiting access to Alzheimer’s treatmentCommentary: A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional FDA approval on Thursday. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access to this new treatment.
Source: chicagotribune - 🏆 8. / 91 Read more »